Dupilumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-Severe Atopic Dermatitis
Conditions
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
Trial Timeline
Mar 21, 2017 → Jun 5, 2018
NCT ID
NCT03054428About Dupilumab + Placebo
Dupilumab + Placebo is a phase 3 stage product being developed by Sanofi for Moderate-to-Severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03054428. Target conditions include Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07053423 | Approved | Recruiting |
| NCT06687967 | Phase 3 | Active |
| NCT06687980 | Phase 3 | Active |
| NCT06191315 | Phase 3 | Recruiting |
| NCT06101095 | Approved | Active |
| NCT05731128 | Phase 2 | Active |
| NCT05097287 | Approved | Recruiting |
| NCT04988022 | Approved | Completed |
| NCT04417894 | Phase 3 | Completed |
| NCT04442269 | Phase 2 | Completed |
| NCT04512339 | Phase 2 | UNKNOWN |
| NCT04400318 | Approved | Completed |
| NCT04033367 | Approved | Completed |
| NCT03749148 | Phase 2 | Completed |
| NCT03749135 | Phase 2 | Completed |
| NCT03633617 | Phase 3 | Completed |
| NCT03389893 | Approved | Terminated |
| NCT03359356 | Phase 2 | Completed |
| NCT03054428 | Phase 3 | Completed |
| NCT02379052 | Phase 2 | Completed |
Competing Products
13 competing products in Moderate-to-Severe Atopic Dermatitis